A PHASE I STUDY OF CODRITUZUMAB, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Phase 1
Completed
- Conditions
- locally advanced or metastatic hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080223270
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Histologically confirmed hepatocellular carcinoma with Glypican-3 staining on tumor by immunohistochemistry >= 2.
- Prior treatment with at least 1 systemic agent.
- Male or female >= 18 years old.
- Eastern Cooperative Oncology Group Performance Status of 0-1.
- Child-Pugh score 5-7.
Exclusion Criteria
- History of autoimmune disease.
- Prior treatment with anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method